GlassScriptPhysician profile
John Paul Magulick
NPI 1356668271
$1,606.72
in general payments reported to CMS, 2019-2025
8 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $28.61 · 2021: $68.04 · 2022: $672 · 2023: $14.20 · 2024: $722 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $722 · Food and Beverage: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $722.17 |
| Food and Beverage | $115.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ovesco Endoscopy USA, INC. | $722.17 | 2024 | |
| Boston Scientific Corporation | $630.29 | 2021-2023 | Axios |
| Olympus America INC. | $124.38 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.25 | 2025 | Entyvio, Eohilia |
| Cook Medical LLC | $28.61 | 2020 | |
| Ardelyx, INC. | $26.19 | 2025 | Ibsrela |
| Novo Nordisk INC | $21.38 | 2025 | Wegovy |
| Abbvie INC. | $20.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Magulick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.